This study is for people with a specific type of blood cancer called B-ALL, which stands for B-cell Acute Lymphoblastic Leukemia. The goal is to see if we can avoid using a treatment called Total Body Irradiation (TBI) for patients who are at low risk of cancer returning. This low risk is determined by a special test called NGS-MRD, which checks for tiny amounts of cancer in the body before a bone marrow transplant. If the test shows no cancer, patients can receive a different kind of treatment without TBI.

Key Points to Consider:

• The study lasts for 2 years with a follow-up period of 3 years.
• Participants will have several blood and bone marrow tests before and after the transplant.
• The study is for those aged 1 to 25, and it is important to have good overall health to join.

This study aims to find safer ways to treat B-ALL by avoiding TBI and using other medicines. If you or someone you know has B-ALL, this study might offer an alternative treatment option, but it requires commitment and meeting specific health criteria.